Suvidhaa Info. (SUVIDHAA)
Asset PlayScore breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1
Key Financials
| Current Price | ₹2.52 |
| Market Cap | ₹53.62 Cr |
| P/E Ratio | 0 |
| ROCE | -32.08% |
| ROE | -30.3% |
| Dividend Yield | 0% |
| Profit Growth | 31.97% |
| Debt/Equity | 0.05 |
| Sales Growth | -60% |
| Promoter Holding | 38.33% |
| 52-Week Range | ₹2 — ₹4.25 |
| Sector | Financial Technology (Fintech) |
| Book Value | ₹1.92 |
Strengths
- Balance sheet has minimal debt (D/E 0.04), reducing insolvency risk
- Trades at a 43% discount to book value (P/B 0.57), providing a theoretical asset cushion
- Promoter holding of 38.33% aligns some interests with public shareholders
- Piotroski F-Score of 5/9 suggests moderate financial health, not outright distress
- Reported profit growth, while from a negative base, shows losses may be narrowing
Concerns
- Revenues are minuscule (₹1 Cr quarterly) and declining at -37.5% year-on-year
- Company is loss-making (latest quarterly net profit ₹-2 Cr) with no clear profitability timeline
- ROCE at -32.08% indicates severe value destruction on invested capital
- Negative ROE (-4.50%) means shareholders' equity is shrinking, not growing
AI Analysis
This is not a business I would confuse with a franchise. Suvidhaa does just ₹1 crore in quarterly sales—that is a lemonade stand, not a fintech titan. Sales are collapsing at -37.5%, and despite the reported 'profit growth' of 31.97%, the latest quarter still shows a net loss of ₹2 crore. The P/E of 0.00 is meaningless; this is a loss-making enterprise. At ₹3.01, the stock trades at 0.57 times book value, so Graham might look at the ₹5.32 per share of net assets. But I have learned that a price below book is only attractive if the book is real and capable of generating earnings. ROCE at -32.08% tells me this capital is being destroyed, not compounded. The low debt-to-equity of 0.04 gives some comfort, but a debt-free sinking ship still sinks. Promoters own 38.33%, which is decent, but small; they have not exactly put their entire being into this. The Piotroski score of 5/9 suggests financial health is mediocre, not pristine. I cannot call this a stalwart or a grower. It is, at best, an asset play with a hope of turnaround. If management can stanch the bleeding, stabilize sales, and show a path to profitability, the discount to book might narrow. But I need evidence of real change, not just a reduced loss. Until I see quarter-after-quarter of improving fundamentals, this remains a speculative stock, not an investment. The market cap of ₹63 crore is tiny; any minor positive news could move it, but negativity has the same power. My margin of safety is only as good as the underlying business, and right now the foundation is shaky.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer